Cargando…

Delayed Contrast Enhancement in Magnetic Resonance Imaging and Vascular Morphology of Primary Diffuse Large B-Cell Lymphoma (DLBCL) of the Central Nervous System (CNS): A Retrospective Study

BACKGROUND: This study aimed to compare the magnetic resonance imaging (MRI) findings of primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (CNS) with delayed contrast enhancement and histological microvessel density (MVD). T1-weighted and T2-weighted contrast-enhanced and n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Dandan, Liu, Xiaojun, Ba, Zhaogui, Xie, Limei, Han, Jiwu, Yu, Dexin, Ma, Xiangxing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2019
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6515976/ https://www.ncbi.nlm.nih.gov/pubmed/31055591 http://dx.doi.org/10.12659/MSM.913439

Ejemplares similares

Apparent Diffusion Coefficient to Subdivide Breast Imaging Reporting and Data System Magnetic Resonance Imaging (BI-RADS-MRI) Category 4 Lesions
por: Liu, Dandan, et al.
Publicado: (2018)

S5-KL-1 CURRENT TREATMENT FOR DLBCL AND PROPHYLAXIS AND TREATMENT FOR SECONDARY CNS LYMPHOMA
por: Izutsu, Koji
Publicado: (2019)

CAR T-cell therapy for secondary CNS DLBCL
por: Ahmed, Gulrayz, et al.
Publicado: (2021)

Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL)
por: Zhang, Wenqi, et al.
Publicado: (2021)

Primary CNS lymphoma other than DLBCL: a descriptive analysis of clinical features and treatment outcomes
por: Lim, Taekyu, et al.
Publicado: (2011)

Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden
por: Harrysson, Sara, et al.
Publicado: (2021)

PB2106: REDUCTION OF METHOTREXATE (MTX) LEVELS AFTER GLUCARPIDASE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AT RISK OF CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT WHO RECEIVE HDMTX: PHASE 2
por: De La Fuente, A., et al.
Publicado: (2022)

Diffuse Large B-Cell Lymphoma (DLBCL) in an Aged Raccoon (Procyon lotor)
por: D’Annunzio, Giulia, et al.
Publicado: (2022)

Identification of key mutations in central nervous diffuse large B-cell lymphoma (DLBCL) by comprehensive analysis between sequencing and TCGA database
por: Zhou, Chunhui, et al.
Publicado: (2021)

PB2334: CENTRAL NERVOUS SYSTEM (CNS) RELAPSE IN DIFFUSE LARGE B-CELL LYMPHOMA: CNS-SAMATYA RISK MODEL
por: Yokus, Osman, et al.
Publicado: (2023)

CNS Involvement of DLBCL Presenting with an Unusual Non-Enhancing Infiltrative Mass
por: Hsueh, Fu-Sheng, et al.
Publicado: (2023)

Retracted: Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL)
por: Markers, Disease
Publicado: (2023)

Diffuse large B-cell lymphoma (DLBCL) with significant intravascular invasion. Close resemblance of its clinicopathological features to intravascular large B-cell lymphoma, but not to DLBCL-not otherwise specified
por: Itami, Hiroe, et al.
Publicado: (2021)

Leptomeningeal relapse in primary cutaneous DLBCL: Implications for a prophylactic CNS therapy
por: Sundriyal, Deepak, et al.
Publicado: (2020)

Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL)
por: Griffiths, Robert, et al.
Publicado: (2010)

Survivin expression in patients with newly diagnosed nodal diffuse large B cell lymphoma (DLBCL)
por: Markovic, O., et al.
Publicado: (2012)

Identification of a 14-Gene Prognostic Signature for Diffuse Large B Cell Lymphoma (DLBCL)
por: Feng, Pengcheng, et al.
Publicado: (2021)

Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options
por: Vodicka, Prokop, et al.
Publicado: (2022)

DLBCL-Morph: Morphological features computed using deep learning for an annotated digital DLBCL image set
por: Vrabac, Damir, et al.
Publicado: (2021)

Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context
por: Abdulhaq, Haifaa, et al.
Publicado: (2023)

Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma
por: Kuitunen, Hanne, et al.
Publicado: (2020)

CAR-T Cell Therapy Shows Similar Efficacy and Toxicity in Patients With DLBCL Regardless of CNS Involvement
por: Shumilov, Evgenii, et al.
Publicado: (2023)

SOCS1 Mutation Subtypes Predict Divergent Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients
por: Schif, Birgit, et al.
Publicado: (2012)

The fear of lymphadenopathy: A cautionary case of sarcoidosis masquerading as recurrent diffuse large b-cell lymphoma (DLBCL)
por: Whooley, Peter D., et al.
Publicado: (2018)

Cost-Effectiveness of Molecularly Guided Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) in Patients under 60
por: Regier, Dean A., et al.
Publicado: (2022)

P1268: DELINEATING THE NEOANTIGEN BURDEN AND TUMOUR MICROENVIRONMENT IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL).
por: Jiang, Y., et al.
Publicado: (2022)

Polymorphisms in DNA Repair and One-Carbon Metabolism Genes and Overall Survival in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma
por: Wang, Sophia S, et al.
Publicado: (2008)

Good outcome of AIDS-related Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) with abbreviated cycles of EPOCH-rituximab
por: Dunleavy, K, et al.
Publicado: (2009)

Clinical outcomes of people living with human immunodeficiency virus (HIV) with diffuse large B-cell lymphoma (DLBCL) in Shanghai, China
por: Sun, Jian-Jun, et al.
Publicado: (2020)

PB2308: NIVOLUMAB-BASED THERAPY OF RELAPSED OR REFRACTORY PRIMARY LARGE B-CELL LYMPHOMA OF IMMUNE-PRIVILEGED SITES AND DLBCL WITH SECONDARY CNS INVOLVEMENT
por: Gavrilenko, Andrey, et al.
Publicado: (2023)

Bone marrow biopsy can be omitted in the diagnostic workup of CNS lymphoma of DLBCL origin: a population-based retrospective study in the PET-CT era
por: Jelicic, Jelena, et al.
Publicado: (2023)

New indications and platforms for CAR‐T therapy in lymphomas beyond DLBCL
por: Iqbal, Madiha, et al.
Publicado: (2021)

The use of FDG-PET in diffuse large B cell lymphoma (DLBCL): predicting outcome following first line therapy
por: Coughlan, Monica, et al.
Publicado: (2014)

Diffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8(+) T-cells despite immune checkpoint signaling
por: Greenbaum, Adam M., et al.
Publicado: (2022)

Extra- and Intracranial Diffuse Large B-Cell Lymphoma (DLBCL) Mimicking Meningioma: A Case Report and Literature Review
por: Matejka, Matthias, et al.
Publicado: (2023)

Subcategorization of suspicious non-mass-like enhancement lesions(BI-RADS-MRI Category4)
por: Liu, Dandan, et al.
Publicado: (2023)

PB2376: ASSAY DEVELOPMENT AND VALIDATION OF IG-HTS TO MONITOR MRD IN PLASMA OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Wu, Jinghua, et al.
Publicado: (2023)

Diffusion-Weighted MRI Reflects Proliferative Activity in Primary CNS Lymphoma
por: Schob, Stefan, et al.
Publicado: (2016)

The Immunology of DLBCL
por: Takahara, Taishi, et al.
Publicado: (2023)

Role of hypoxia in Diffuse Large B-cell Lymphoma: Metabolic repression and selective translation of HK2 facilitates development of DLBCL
por: Bhalla, Kavita, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_spvi2ff6qlbhj4uj0un5ls4muq